Mirum Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
MIRM$94.42+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Deficit · Income (Loss) · Equity | ||||||||
| Balance as of December 31, 2020 | 29,776,544 | $3 | $345,180 | $(173,171) | $83 | $172,095 | ||
| Issuance of common stock in connection with equity incentive plans | 207,595 | — | 844 | — | — | 844 | ||
| Issuance of common stock in connection with public offering, net of issuance costs of $476 | 375,654 | — | 7,038 | — | — | 7,038 | ||
| Restricted common stock vested in the period | 133,592 | — | — | — | — | — | ||
| Issuance of common stock in connection with Employee Stock Purchase Plan | 89,211 | — | 1,254 | — | — | 1,254 | ||
| Stock-based compensation | — | — | 23,087 | — | — | 23,087 | ||
| Net loss | — | — | — | (83,988) | — | (83,988) | ||
| Other comprehensive loss | — | — | — | — | (118) | (118) | ||
| Balance as of December 31, 2021 | 30,582,596 | $3 | $377,403 | $(257,159) | $(35) | $120,212 | ||
| Issuance of common stock in connection with asset acquisition | 609,305 | — | 15,585 | — | — | 15,585 | ||
| Issuance of common stock in connection with equity incentive plans | 357,934 | — | 5,438 | — | — | 5,438 | ||
| Issuance of common stock in at-the-market offerings, net of issuance costs of $785 | 1,160,915 | — | 21,289 | — | — | 21,289 | ||
| Issuance of common stock in connection with public offering, net of issuance costs $5,922 | 4,000,000 | 1 | 86,077 | — | — | 86,078 | ||
| Restricted common stock vested in the period | 122,464 | — | — | — | — | — | ||
| Issuance of common stock in connection with Employee Stock Purchase Plan | 123,131 | — | 1,834 | — | — | 1,834 | ||
| Stock-based compensation | — | — | 27,448 | — | — | 27,448 | ||
| Net loss | — | — | — | (135,665) | — | (135,665) | ||
| Other comprehensive loss | — | — | — | — | (182) | (182) | ||
| Balance as of December 31, 2022 | 36,956,345 | $4 | $535,074 | $(392,824) | $(217) | $142,037 | ||
| Issuance of common stock in private placement, net of issuance costs of $7,796 | 8,000,000 | 1 | 202,203 | — | — | 202,204 | ||
| Issuance of common stock in at-the-market offerings, net of issuance costs of $518 | 658,206 | — | 14,480 | — | — | 14,480 | ||
| Issuance of common stock in connection with asset acquisition | 231,624 | — | 5,188 | — | — | 5,188 | ||
| Issuance of common stock in connection with equity award plans | 760,226 | — | 8,279 | — | — | 8,279 | ||
| Issuance of common stock in connection with employee stock purchase plan | 116,742 | 2,191 | 2,191 | |||||
| Stock-based compensation | — | — | 35,845 | — | — | 35,845 | ||
| Net loss | — | — | — | (163,415) | — | (163,415) | ||
| Other comprehensive income | — | — | — | — | 1,861 | 1,861 | ||
| Balance as of December 31, 2023 | 46,723,143 | $5 | $803,260 | $(556,239) | $1,644 | $248,670 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.